Department of Chemistry, University of South Florida, CHE 205, 4202 E. Fowler Avenue, Tampa, Florida 33620, USA.
J Med Chem. 2010 Oct 14;53(19):7076-94. doi: 10.1021/jm1007903.
Since the 1940s endochin and analogues thereof were known to be causal prophylactic and potent erythrocytic stage agents in avian models. Preliminary screening in a current in vitro assay identified several 4(1H)-quinolones with nanomolar EC(50) against erythrocytic stages of multidrug resistant W2 and TM90-C2B isolates of Plasmodium falciparum. Follow-up structure-activity relationship (SAR) studies on 4(1H)-quinolone analogues identified several key features for biological activity. Nevertheless, structure-property relationship (SPR) studies conducted in parallel revealed that 4(1H)-quinolone analogues are limited by poor solubilities and rapid microsomal degradations. To improve the overall efficacy, multiple 4(1H)-quinolone series with varying substituents on the benzenoid quinolone ring and/or the 3-position were synthesized and tested for in vitro antimalarial activity. Several structurally diverse 6-chloro-2-methyl-7-methoxy-4(1H)-quinolones with EC(50) in the low nanomolar range against the clinically relevant isolates W2 and TM90-C2B were identified with improved physicochemical properties while maintaining little to no cross-resistance with atovaquone.
自 20 世纪 40 年代以来,人们已经知道内源性化合物及其类似物是禽类模型中针对疟原虫红内期的有效预防和治疗药物。目前,在一项体外检测中,初步筛选出了几种对多药耐药 W2 和 TM90-C2B 疟原虫分离株的红细胞期具有纳摩尔 EC50 的 4(1H)-喹诺酮类化合物。对 4(1H)-喹诺酮类似物的后续结构活性关系 (SAR) 研究确定了几个关键的生物活性特征。然而,同时进行的结构-性质关系 (SPR) 研究表明,4(1H)-喹诺酮类似物受到较差的溶解度和快速的微粒体降解的限制。为了提高整体疗效,我们合成了多个苯并喹诺酮环和/或 3 位带有不同取代基的 4(1H)-喹诺酮系列化合物,并对其体外抗疟活性进行了测试。鉴定出了几种结构多样的 6-氯-2-甲基-7-甲氧基-4(1H)-喹诺酮类化合物,对临床相关分离株 W2 和 TM90-C2B 的 EC50 达到纳摩尔级,同时改善了理化性质,而与阿托伐醌的交叉耐药性则很小或没有。